Alpine Immune Sciences to Present at Jefferies 2018 Global Healthcare Conference

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

May 22, 2018 07:00 am
SEATTLE -- 

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5 2018 at 4:30 pm Eastern Time in New York, NY.

A live webcast of the presentation will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of the presentation will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies based upon its variant Ig Domain (vIgD) technology. vIgDs are engineered to interact with multiple immune targets, including many present in the immune synapse. Alpine’s vIgDs are developed with its proprietary platform technology utilizing a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and making vIgD-based therapeutics potentially capable of treating cancer, autoimmune/inflammatory, and other diseases. Alpine has also developed Transmembrane Immunomodulatory Protein (TIP) technology, based on vIgD technology, to potentially enhance engineered cellular therapies. For more information, visit www.alpineimmunesciences.com.

For Alpine Immune Sciences, Inc.
Investor Relations
Pure Communications, Inc.
Courtney Dugan, 212-257-6723
[email protected]

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).